Quick Hits: Abuse Warning for Rx Testosterone, a Second Chance for Kratom & More

Quick Hits: Transvaginal Mesh Pulled, New Weight Loss Drug & More

The FDA is adding a warning to all prescription testosterone products regarding abuse and dependence risks. Prescription testosterone was already designated a Schedule III controlled substance due to safety risks impacting the heart, brain, liver, mental health and endocrine system if taken more than directed. Additional case reports indicate that abuse of testosterone can lead to withdrawal symptoms such as depression, fatigue, irritability, loss of appetite, decreased libido and insomnia. Testosterone is prescribed to men as hormone replacement therapy, usually due to medical conditions such as genetic issues or chemotherapy. Posted October 25, 2016. Via FDA.

The DEA (Drug Enforcement Administration) will hold off on banning kratom, a plant said to have analgesic effects and an alternative to opioid painkillers, to entertain public comment. In late August, the DEA said it would designate kratom a Schedule I drug, meaning it has no medicinal value and a high risk of abuse. Other drugs in this category include heroin, LSD and marijuana. The DEA also said it will receive a scientific and medical recommendation on kratom from the FDA. The comment period ends on December 1, 2016. Posted October 13, 2016. Via Federal Register.

A new antipsychotic in development has been shown to have no additional side effects compared to a placebo in a late-stage trial. The drug, known as ITI-007, also demonstrated significant reduction in psychosis 4 weeks after patients began treatment. The researchers said the drug may provide similar efficacy to Risperdal (risperidone), but without the side effects associated with that drug. Whether ITI-007 will be approved by the FDA is questionable since a second Phase III trial of the drug showed no better efficacy than a placebo. Posted October 18, 2016. Via Medscape Medical News.


Jonathan Block

Jonathan Block

Jonathan Block is a freelance writer and former MedShadow content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including BioCentury, The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

Synthetic Red Blood Cells, NOAC’s for Atrial Fibrillation, Surgery to Ease Sciatica Pain

Synthetic Red Blood Cells, NOAC’s for Atrial Fibrillation, Surgery to Ease Sciatica Pain

Researchers have managed to create artificial red blood cells that can transport medication. Compared to the popular anticoagulant Warfarin, NOAC’s may be superior for treating atrial fibrillation patients with prior intracranial hemorrhage. Also, surgery may be the preferred choice for reducing leg pain in patients with sciatica.  Synthetic Red Blood…

FDA Recalls Metformin and NP Thyroid

FDA Recalls Metformin and NP Thyroid

The FDA has issued a recall of two drugs–NP Thyroid and Metformin–after testing revealed that they weren’t up to code. Read more below, and if you’re taking either medication, please be sure to contact your doctor for how to continue treatment responsibly.  NP Thyroid Recalled Thirteen lots of NP Thyroid,…

  • Advertisement